AGSAVI vs Valsartan/amlodipine/chlorthalidone (AJU-C52)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Angiotensin II receptor / Calcium channel / Thiazide-like diuretic · full Hypertension pipeline
AGSAVI
Marketed by Ahn-Gook Pharmaceutical
NCT05503953 · Phase 3 · completed
The study was randomized, double-blind, and active-controlled, with 318 participants, and evaluated a clinical blood-pressure endpoint. Because the registry does not report whether the primary comparison was statistically significant, the findings cannot be classified as demonstrating a positive effect.
No aligned efficacy figure on record for this race.
Valsartan/amlodipine/chlorthalidone (AJU-C52)
Developed by AJU Pharm
NCT06416865 · Phase 3 · completed
The trial was randomized with full blinding of participants, care providers, investigators, and outcome assessors, used an active dual-therapy comparator, enrolled a reasonably sized cohort for a blood-pressure trial, and measured a hard, disease-defining physiological endpoint (systolic blood pressure change) rather than a lab biomarker. A sourced result shows the triple-combination arm achieved a clearly favorable and clinically meaningful reduction in blood pressure versus the active comparator, meeting the primary endpoint.
Reported efficacy
Changes in MSSBP(mean sitting systolic blood pressure) (8th week): Change in MSSBP from baseline to week 8: between-group difference of -10.99 (valsartan/amlodipine/chlorthalidone vs valsartan/amlodipine control) (met)
Result source: NCT06416865
Results for Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | AGSAVI | Valsartan/amlodipine/chlorthalidone (AJU-C52) |
|---|---|---|
| Seated SBP, change | —Not posted · NCT05503953 | —Not posted · NCT06416865 |
| 24-hour ambulatory SBP, change | —Not posted · NCT05503953 | —Not posted · NCT06416865 |
| Seated DBP, change | —Not posted · NCT05503953 | —Not posted · NCT06416865 |
Seated SBP, change
- AGSAVI
- —Not posted · NCT05503953
- Valsartan/amlodipine/chlorthalidone (AJU-C52)
- —Not posted · NCT06416865
24-hour ambulatory SBP, change
- AGSAVI
- —Not posted · NCT05503953
- Valsartan/amlodipine/chlorthalidone (AJU-C52)
- —Not posted · NCT06416865
Seated DBP, change
- AGSAVI
- —Not posted · NCT05503953
- Valsartan/amlodipine/chlorthalidone (AJU-C52)
- —Not posted · NCT06416865
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
AGSAVI: no structured comparison results are available for Hypertension.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AGSAVI's landscape · Valsartan/amlodipine/chlorthalidone (AJU-C52)'s landscape